SecBot SecBot
Biotech Drug Report Generated Nov 10, 2026

Tyrvaya

VTRS·Viatris Inc
NEUTRAL
Drug Impact Rating4/10
Trial phase
Approved
Time to market
Already approved and commercialized since October 2021.
Why 4/10
Tyrvaya is already FDA-approved and commercialized with no pending regulatory decision; the defining binary (FDA approval in October 2021) passed years ago. For Viatris, the drug was divested in October 2026 and is no longer a material part of the thesis. For Harrow, the next catalyst is commercial execution (sales ramp), which is not a hard binary catalyst. Impact score is 4 per the rubric for an approved drug with no pending regulatory decision.
Actionable Insight NEUTRAL

Tyrvaya is now owned by Harrow (HROW), not Viatris (VTRS). The next catalyst is Harrow's commercial execution: Tyrvaya closed on October 5, 2026, so its contribution to Harrow's Q4 2026 and full-year 2027 results will be the key metric to watch. Harrow expects Tyrvaya to add more than $30M in 2027 revenue. For Viatris, Tyrvaya is a divested non-core asset with no further impact.

Price Chart

Loading chart...

Executive Summary

Tyrvaya (varenicline solution) is an FDA-approved nasal spray for dry eye disease, first approved in October 2021 as the first and only nasal spray for this indication. Originally developed by Oyster Point Pharma, it was acquired by Viatris (VTRS) in early 2023 as part of a broader ophthalmology push. However, Viatris sold the global rights to Harrow (HROW) in August 2026 for up to $100M, with the deal closing on October 5, 2026. For Viatris, Tyrvaya is now a divested non-core asset. For Harrow, Tyrvaya is a differentiated product expected to contribute more than $30M in 2027 revenue, complementing its existing ophthalmic portfolio. The drug faces competition from established dry-eye drops but offers a novel nasal-spray delivery mechanism that stimulates natural tear production.

How It Works

Tyrvaya is a nasal spray that delivers varenicline, a chemical that activates certain nerve receptors (nicotinic acetylcholine receptors) in the nose. This stimulation triggers the trigeminal parasympathetic pathway, a natural nerve circuit that signals the tear glands to produce more of the eye's own basal tears. Unlike eye drops that add artificial moisture, Tyrvaya aims to boost the body's natural tear production.

Trial Status

FDA-approved in October 2021 based on the ONSET-1 and ONSET-2 Phase 3 clinical trials, which showed statistically significant increases in tear production (Schirmer's score) at 4 weeks. The drug has been commercially available in the U.S. since November 2021 and is also approved in China and other markets.

The Two-Sided Case

▲ Bull Case4
Tyrvaya is the first and only FDA-approved nasal spray for dry eye disease, a novel and differentiated delivery mechanism that avoids eye-drop application and may appeal to patients with tolerability issues with topical drops.
Harrow expects Tyrvaya to add more than $30M in 2027 revenue, and the company reported record Q3 2026 revenue of $99.3M, demonstrating strong commercial momentum across its portfolio.
Analyst consensus on Harrow (HROW) is Strong Buy, with a mean price target of $63 (134% implied upside from the $26.89 close), reflecting optimism about the Tyrvaya acquisition and broader product lineup.
Tyrvaya is also approved in China and other markets, providing geographic expansion optionality beyond the U.S.
▼ Bear Case4
Tyrvaya faces entrenched competition from established dry-eye therapies including Restasis (cyclosporine), Xiidra (lifitegrast), Cequa, and numerous artificial tear products, all of which are eye drops that may be more familiar to patients and prescribers.
Harrow paid up to $100M ($30M upfront plus up to $70M in sales milestones), creating financial pressure to grow the brand quickly; if Tyrvaya sales underwhelm, Harrow may not achieve the milestone revenue targets.
As a nasal spray for an eye condition, Tyrvaya has a novel delivery mechanism that may face adoption resistance from patients and eye-care professionals accustomed to topical drops.
Harrow reported a GAAP net loss in Q2 2026 and carries significant accounts receivable ($118.6M), raising questions about cash collection and the cost of ramping Tyrvaya sales.

Upcoming Catalysts

  • Harrow Q4 2026 earnings (early 2027) - first full quarter of Tyrvaya ownership
  • Harrow full-year 2027 revenue guidance - Tyrvaya expected to contribute >$30M
  • Potential geographic expansion milestones in ex-U.S. markets

Source Filing

The SecBot filing or press-release report that triggered this drug report:

Viatris Inc 8-K VTRS ·Originating report

Sources · 9

Hover a chip for the title
1 empr.com2 nasdaq.com3 kdvr.com4 markets.businessinsider.com5 seekingalpha.com6 healthline.com7 webmd.com8 msn.com9 markets.businessinsider.com